Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable

Eur Heart J. 2002 Mar;23(6):444-57. doi: 10.1053/euhj.2001.2751.

Authors

F W G Leebeek¹, E Boersma, C P Cannon, F J J van de Werf, M L Simoons

Affiliation

¹ Department of Hematology, Erasmus University Medical Center Rotterdam, The Netherlands.

PMID: 11863347
DOI: 10.1053/euhj.2001.2751

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Oral
Cardiovascular Diseases / drug therapy*
Clinical Trials as Topic
Humans
Platelet Aggregation Inhibitors / pharmacology
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*

Substances

Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex